BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1622 related articles for article (PubMed ID: 33294831)

  • 41. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
    Li L; Hai J; Li Z; Zhang Y; Peng H; Li K; Weng X
    Food Chem Toxicol; 2014 Jan; 63():166-73. PubMed ID: 23978414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MMP10 alleviates non-alcoholic steatohepatitis by regulating macrophage M2 polarization.
    Chang L; Gao J; Yu Y; Liao B; Zhou Y; Zhang J; Ma X; Hou W; Zhou T; Xu Q
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111045. PubMed ID: 37844469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis.
    Sun BL; Sun X; Kempf CL; Song JH; Casanova NG; Camp SM; Reyes Hernon V; Fallon M; Bime C; Martin DR; Travelli C; Zhang DD; Garcia JGN
    FASEB J; 2023 Mar; 37(3):e22825. PubMed ID: 36809677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
    Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
    Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatoprotective Effects of
    Ikewaki N; Levy GA; Kurosawa G; Iwasaki M; Dedeepiya VD; Vaddi S; Senthilkumar R; Preethy S; Abraham SJK
    J Clin Exp Hepatol; 2022; 12(6):1428-1437. PubMed ID: 36340302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A human liver chimeric mouse model for non-alcoholic fatty liver disease.
    Bissig-Choisat B; Alves-Bezerra M; Zorman B; Ochsner SA; Barzi M; Legras X; Yang D; Borowiak M; Dean AM; York RB; Galvan NTN; Goss J; Lagor WR; Moore DD; Cohen DE; McKenna NJ; Sumazin P; Bissig KD
    JHEP Rep; 2021 Jun; 3(3):100281. PubMed ID: 34036256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.
    Zhang T; Hu J; Wang X; Zhao X; Li Z; Niu J; Steer CJ; Zheng G; Song G
    J Hepatol; 2019 Jan; 70(1):87-96. PubMed ID: 30218679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The fecal mycobiome in non-alcoholic fatty liver disease.
    Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
    J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway.
    Deng YF; Xu QQ; Chen TQ; Ming JX; Wang YF; Mao LN; Zhou JJ; Sun WG; Zhou Q; Ren H; Zhang YH
    Phytomedicine; 2022 Sep; 104():154241. PubMed ID: 35749827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
    J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
    Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.